Saskatchewan joined 5 provinces and 1 territory in implementing a biosimilar switching policy, allowing for reference products to be switched out for biosimilars and lowering drug costs for the province’s public health plan.
The Saskatchewan Ministry of Health announced that it will implement a biosimilars switching policy, making it the sixth Canadian province and seventh jurisdiction to do so. Saskatchewan joins British Columbia (BC), Quebec, Alberta, New Brunswick, Nova Scotia, and the Northwest Territories.
“This initiative will ensure access to high-quality, essential medications for Saskatchewan residents remains sustainable into the future…. The savings will be reinvested into the Saskatchewan Drug Plan to support patient access to public drug coverage and new drug benefits,” Paul Merriman, health minister of Saskatchewan, commented.
John Esdaile, MD, scientific director of Arthritis Research Canada applauded BC’s program and its transition plan, saying that it could ease Saskatchewan citizens who may be worried about their prescriptions changing.
“Having successfully gone through the transition process with patients in BC starting in 2019, patients and providers should feel confident about the transitioning to biosimilars in Saskatchewan,” he said.
In BC, eligible patients were alerted in advance that their prescriptions would be changed to a biosimilar. The program was rolled out in multiple phases, which each progression adding more originators to the list of biologics that would no longer be covered by the province’s public health plan.
Biosimilars Canada, a national association representing the biosimilar industry in Canada, released a statement on the measure, saying that it hopes that the remaining provinces and territories (Ontario, Manitoba, Newfoundland and Labrador, Prince Edward Island, Yukon, and Nunavut) will follow in Saskatchewan’s footsteps to implement similar policies.
According to the organization, about 24,000 patients in Saskatchewan who are being treated with an originator biologic are expected to transition to a biosimilar version over the next 6 months.
Although biologic drugs have been revolutionary in the fight to treat several chronic conditions and cancers, originator biologics can cost between $10,000 and $25,000 or more annually per patient, which can place a large financial strain on drug budgets. The Ministry of Health estimated that Saskatchewan could save $20 million once the transition period is complete.
“Biosimilars Canada congratulates Health Minister Paul Merriman and the government of Saskatchewan for implementing a biosimilar switching policy and reinvesting the savings to support patient access to public drug coverage and new drug benefits…. Expanding the use of biosimilars through a switching policy is an important way to ensure the sustainability of drug plans and make the most effective use of taxpayer dollars,” said Jim Keon, president of Biosimilars Canada.
The statement comes shortly after the advocacy group held a press conference calling on Doug Ford, the premier of Ontario, to put a biosimilar switching initiative in place in the province.
Patients who are covered by the Saskatchewan Drug Plan and use certain biologic drugs to treat conditions including arthritis, diabetes, inflammatory bowel disease, and psoriasis will have to switch to a biosimilar version of their medicine by April 30, 2023. Canada currently has 49 approved biosimilars.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.